Adenovirus (Ad) vectors based on human Ad type 5 (hAd5 vector) are widely used for gene transfer studies and clinical gene therapy trials because they can achieve high transduction efficiency and transduce both dividing and non-dividing cells. 1, 2 However, one of the hurdles confronting hAd5-mediated gene transfer is that hAd5 infection is dependent on the expression levels of the primary receptor for hAd5, the coxsackievirus and adenovirus receptor (CAR), on the surface of target cells. hAd5 vectors generally cannot efficiently transfer genes of interest into cells lacking CAR expression (that is, many advanced tumor cells, peripheral blood cells, vascular smooth muscle cells (SMCs), dendritic cells, hematopoietic stem cells, so on), although there are some exceptions. [3] [4] [5] Genetic modification of the hAd5 capsid, such as the insertion of foreign ligands into fiber, protein IX (pIX), or hexon or the substitution by the chimeric fibers with knob (and shaft) derived from nonhuman Ads or from human Ads belonging to other subgroups, is an attractive strategy for overcoming CAR-dependent infection. Several groups, including us, have generated various types of capsid-modified hAd5 vectors, such as hAd5 vectors containing an RGD (Arg-Gly-Asp) peptide or a poly-lysine (KKKKKKK;K7) peptide in the fiber knob, pIX, or hexon. [6] [7] [8] [9] [10] [11] [12] [13] [14] These capsid-modified hAd5 vectors efficiently infect CAR-negative cells via interaction between cellular av integrin/heparan sulfate proteoglycans and RGD/poly-lysine peptides on the capsid. However, in blood cells, which are known to resist efficient transduction, the enhancement of transduction by the use of fiber-modified hAd5 vectors was limited compared with that in adherent cells.
Protein transduction domains (PTDs) have been used to deliver various types of bioactive substrates, such as proteins, antisense oligonucleotides, siRNAs, liposomes and plasmid DNAs, into cells. 15 The short sequences of 10-30 amino acids, which are highly rich in basic residues in the PTDs, are responsible for their ability to deliver substrates into cells. The TAT peptide (GRKKRRQRRRPQ) is derived from the transactivator of transcription (TAT) of human immunodeficiency virus and is the most highly investigated PTD. There are many reports about the utility of the TAT peptide for the intracellular delivery of macromoleculars (reviewed in Gupta et al.
15
), although its precise mode of action still remains to be clarified.
In the present study, to broaden the tropism of hAd5 vectors, we genetically modified hAd5 vectors with the TAT peptide. We generated hAd5 vectors containing the TAT peptide in the HI loop or the C-terminus of the fiber protein and compared their gene transfer activity with that of conventional hAd5 vectors and hAd5 vectors in which an RGD peptide was inserted into the HI loop of the fiber knob or a poly-lysine peptide was added to the C-terminus of the same protein.
First, hAd5 vectors containing the TAT peptide in the HI loop of the fiber knob (Ad-TAT(HI)-L2) or the C-terminus of the fiber knob (Ad-TAT(C)-L2) were constructed using an improved in vitro ligation method that had been reported previously. 12, 16, 17 In brief, the oligonucleotides encoding the TAT 48-60 peptide (GRKKR RQRRRPQ) were inserted into a Csp45I site in the fiber-HI loop or a ClaI site in the fiber-C-terminal-coding region of the pAdHM41. 12 Detailed information about the construction of the vector plasmids for the hAd5 vectors containing the TAT peptide in the HI loop of the fiber knob (pAdHM41-TAT(HI)-L2) or the C-terminus of the fiber knob (pAdHM41-TAT(C)-L2) is available from the authors upon request. To generate the virus, pAdHM41-TAT(HI)-L2 and pAdHM41-TAT(C)-L2 were digested with PacI. Linearized DNAs were transfected into 293 cells plated on a 60-mm dish with SuperFect (QIAGEN Inc., Valencia, CA, USA) according to the manufacturer's instructions. Ad-TAT(HI)-L2 and Ad-TAT(C)-L2 were prepared as described previously. 16, 17 The conventional hAd5 vectors (Ad-L2) and the fibermodified hAd5 vectors containing an RGD-4C (CDC RGDCFC) peptide 18 in the HI loop of the fiber knob (Ad-RGD-L2) or a poly-lysine peptide (KKKKKKK;K7) in the C-terminus of the fiber knob (Ad-K7-L2) were constructed previously. 10, 12 All hAd5 vectors used in the present study have the same luciferase expression cassette under the control of cytomegalovirus (CMV) promoter. The determination of virus particle titers (VP) was accomplished spectrophotometrically by the method of Maizel et al. 19 The growth rates of Ad-TAT(HI)-L2 and Ad-TAT(C)-L2 were slightly lower than those of Ad-L2. The yields of Ad-TAT(HI)-L2 and Ad-TAT(C)-L2 were approximately 10-fold lower than those of Ad-L2 (data not shown). The positive charge of the TAT peptide might be involved in low yields of TAT-modified hAd5 vector. The presence of the TAT peptide in the hAd5 capsid may also affect fiber maturation, viral encapsidation and so on, since the electric charge of hAd5 vector is negative. The growth rates and the yields of Ad-RGD-L2 and Ad-K7-L2 were similar to those of Ad-L2. The hAd5 vectors used in the present study are summarized in Table 1 .
Next, we compared the gene transfer activities of each type of hAd5 vector in several types of human cell lines ( Figure 1 ). LN444 and SF295 cells were CAR-negative, while SK HEP-1 cells were CAR-positive. 9 The luciferase production in the CAR-negative adherent cell lines (LN444 and SF295) transduced with Ad-TAT(HI)-L2
and Ad-TAT(C)-L2 was approximately 50-500 times higher than that observed with Ad-L2. In a CAR-positive cell line, SK HEP-1, the luciferase production by Ad-TAT(HI)-L2 was approximately 10-fold higher than that by Ad-L2, while the luciferase production by Ad-TAT(C)-L2 was similar to that by Ad-L2 (it is unclear whether Ad-TAT(HI)-L2 and Ad-TAT(C)-L2 infect SK HEP-1 cells via a CAR-dependent pathway or a TAT-mediated pathway). Furthermore, the gene expression levels of Ad-TAT(HI)-L2 in CAR-negative cells were approximately 10-fold higher than those of Ad-RGD-L2 and Ad-K7-L2, which have been demonstrated to transduce efficiently CAR-negative cells. 9, 10, 12 Ad-TAT(C)-L2 mediated transduction efficiencies at levels similar to Ad-RGD-L2 and Ad-K7-L2. In the case of transduction experiments with lower vector doses (300 VP/cell), same results were obtained (data not shown). These results indicate that TAT-modified hAd5 vectors possess higher gene transfer activity than RGD-or K7-modified hAd5 vectors at last in the cell lines used in the present study. The precise mechanism by which Ad-TAT(HI)-L2 was superior to Ad-TAT(C)-L2 is unknown. In the case of hAd5 vectors containing an RGD peptide, the modification of the HI loop of the fiber knob was more effective than that of the C-terminus. 12, 14 On the other hand, in the case of hAd5 vectors containing a poly-lysine peptide, only the modification of the C-terminus affected the transduction efficiency (the modification of the HI loop with a poly-lysine had no effect). 12 Therefore, the suitable location for modification would be dependent on the peptide itself.
We then compared the gene transfer activities of each type of hAd5 vector in human blood cells (U937 and Jurkat) (Figure 2a ) or in two types of human primarycultured vascular SMCs (Figure 2b ). Blood cells and SMC are well known to be refractory to conventional hAd5 vector-mediated transduction. In U937 cells (human histiocytic lymphoma), Ad-L2 did not mediate luciferase production; however, Ad-TAT(HI)-L2 mediated higher gene expression than Ad-RGD-L2 and Ad-K7-L2, which were superior to Ad-L2. Luciferase production in Jurkat cells (human acute T-cell leukemia) transduced with Ad-TAT(HI)-L2 was roughly similar (approximately 1.5-and 2-fold superior) to that observed with Ad-RGD-L2 and Ad-K7-L2, respectively, while that observed with Ad-TAT(HI)-L2 was approximately 10-fold higher than that observed with Ad-L2. In human CSMC (coronary smooth muscle cells, obtained from Cambrex Bio Science Walkersville, MD, USA), Ad-TAT(HI)-L2 showed higher luciferase production than did other types of hAd5 Genetically
In human ASMC (aortic smooth muscle cells, obtained from Cambrex Bio Science Walkersville), luciferase production by Ad-TAT(HI)-L2 was approximately 100-fold higher than that by Ad-L2 and 10-fold higher than that by Ad-RGD-L2 and that by Ad-K7-L2. Thus, Ad-TAT(HI)-L2 showed the highest in vitro gene transfer activity among the hAd5 vectors used in the present study. However, luciferase production in U937 and Jurkat cells transduced with Ad-TAT(HI)-L2 were 1-2 log orders lower than those in LN444, SF295 and SK HEP-1 cells. Moreover, no luciferase production occurred in HL60 (acute promyelotic leukemia) or molt-4 cells (acute lymphoblastic leukemia) after transduction with all of the types of hAd5 vectors examined here (data not shown). These results suggested that other factors expect for binding of Ad vectors to the cellular surface (receptor) might explain the low-transduction efficiencies of hAd5 vectors in blood cells, since the TAT peptide can enter into blood cells, such as human CD34 + cells. 20 We have previously reported that in addition to the receptor expression in target cells, the choice of promoters that drive transgene expression is another crucial determinant of gene expression efficiency in mouse embryonic stem cells and human hematopoietic progenitors. 21, 22 In the present study, we used a CMV promoter, which is generally regarded as one of the most powerful promoters and is widely used in transduction experiments. In addition to modification of the viral capsid, optimization of the promoters should be required to overcome low gene expression in blood cells.
Next, to clarify the infection mechanism of TATmodified hAd5 vectors, we investigated whether 
Ad-TAT(HI)-L2 infects cells via the interaction between
the TAT peptide and heparan sulfate proteoglycans on the cell surface. Several groups reported that cellular surface proteoglycans such as heparan sulfate act as one of the receptors for the TAT peptide. 15, 23, 24 We investigated the effect of heparinase I (Sigma, St Louis, MO, USA) on the transduction efficiencies of Ad-L2, Ad-TAT(HI)-L2 and Ad-K7-L2 (Figure 3 ). CAR-negative LN444 cells were used to minimize the effects of the CAR-dependent pathway of hAd5 infection. The results showed that the transduction efficiency of Ad-TAT(HI)-L2 in LN444 cells was not reduced by pre-treatment with heparinase I, while heparinase I inhibited the transduction with Ad-K7-L2 in a dose-dependent manner (Figures 3b and c) . This result suggests that the infection mechanism of Ad-TAT(HI)-L2 is different from that of Ad-K7-L2. The precise mechanism for transduction with Ad-TAT(HI)-L2 remains unclear. Other studies proposed that a 90 kDa cell surface protein or avb5 integrin are cellular receptors of the TAT 49-57 domain (RKKRR QRRR). 25, 26 In the present study, we used the TAT 48-60 peptide (GRKKRRQRRRPQ) for modification of hAd5 vector. Ad-TAT(HI)-L2 might infect cells via the interaction with the proteoglycans, 90-kDa cell surface protein, avb5 integrin and/or other unknown receptors.
Finally, to examine the in vivo transduction efficiency of Ad-TAT(HI)-L2, we intravenously administered Ad-L2 or Ad-TAT(HI)-L2 (1.0 Â 10 10 VP/mouse) to C57BL/6 mice (female, 7 weeks old; obtained from Nippon SLC, Shizuoka, Japan) and measured the luciferase production in the organs. Ad-TAT(HI)-L2 efficiently mediated luciferase production in the liver, spleen, lung, kidney, heart and brain (Figure 4) . In contrast, Ad-TAT(HI)-L2 mediated approximately 7-folds higher gene expression in the lung than did Ad-L2. Schwarze et al. 27 previously reported that b-galactosidase that was fused with the TAT peptide at its N terminus reached the brain after intraperitoneal administration and maintained its b-galactosidase activity, while unmodified b-galactosidase did not. Therefore, we also examined the luciferase production in the brain. Luciferase production in the brain after intravenous administration of Ad-TAT(HI)-L2 was equal to that after administration of Ad-L2. These results indicate that in the case of systemic administration, the TAT peptide improves the transduction efficiency of the hAd5 vector into the lung, although liver transduction is 3 log orders higher than lung transduction.
Gratton et al. 28 and Kuhnel et al. 29 previously reported the utility of PTDs, including the TAT peptide, on hAd5 vector-mediated transduction. Gratton et al. 28 constructed a complex between hAd5 vectors and the Antp peptide, which is a PTD derived from Drosophila, via electrostatic interaction between the high positive charge of PTD and the negative charge of hAd5 capsid and succeeded in efficient transduction into carotid arteries ex vivo and adductor muscle in vivo mice model after intramuscular administration. Kuhnel et al. 29 chemically bound the TAT peptide to hAd5 vectors using the ectodomain of CAR fused with the TAT peptide as an adaptor to the fiber knob and showed the enhancement Genetically modified Ad vectors containing HIV-1 TAT peptide S Kurachi et al of hAd5 vector transduction to several tumor cell lines and the possibility of an application for conditionally replicative oncolytic Ad vector. In the present study, we simply generated TAT-modified hAd5 vectors by genetic insertion of the TAT peptide into the fiber knob and succeeded in improving transgene expression in the cells, which are refractory to conventional hAd5 vectors. TAT-modified Ad vector generated in the present study would be superior to electrostatically or chemically modified Ad vectors with Antp-or TAT-peptide because genetically-modified vectors are uniform and batch-tobatch difference of the vectors should be minimum.
In summary, to broaden the tropism of hAd5 vectors, we generated novel fiber-modified Ad vectors that contain the TAT peptide in the HI loop of the fiber knob or the C-terminus of the fiber knob. These hAd5 vectors can effectively transduce cells in a CAR-independent manner. These hAd5 vectors are an attractive tool for transducing cells and can be useful as a platform vector for gene therapy, including ex vivo gene therapy, genemodified cell therapy, cancer gene therapy using a conditionally replicative oncolytic hAd5 vector, and so on. 10 VP/mouse) were intravenously injected into the mice. Two days later, the liver, spleen, lung, kidney, heart and brain were harvested, and luciferase production was determined using a luciferase assay system (PicaGene 5500; Toyo Ink Co.), as previously described. 30 All data represent the means7s.d. of five mice. Statistical significance was evaluated by unpaired Student's t-test. *Po0.001 Genetically modified Ad vectors containing HIV-1 TAT peptide S Kurachi et al
